Safety of Early Discontinuation of Antiseizure Medication After Acute Symptomatic Neonatal Seizures.

Published on Jul 1, 2021in JAMA Neurology13.608
· DOI :10.1001/JAMANEUROL.2021.1437
Hannah C. Glass37
Estimated H-index: 37
(UCSF: University of California, San Francisco),
Janet S. Soul37
Estimated H-index: 37
(Boston Children's Hospital)
+ 14 AuthorsRenée A. Shellhaas32
Estimated H-index: 32
(UM: University of Michigan)
Sources
Abstract
Importance Antiseizure medication (ASM) treatment duration for acute symptomatic neonatal seizures is variable. A randomized clinical trial of phenobarbital compared with placebo after resolution of acute symptomatic seizures closed early owing to low enrollment. Objective To assess whether ASM discontinuation after resolution of acute symptomatic neonatal seizures and before hospital discharge is associated with functional neurodevelopment or risk of epilepsy at age 24 months. Design, Setting, and Participants This comparative effectiveness study included 303 neonates with acute symptomatic seizures (282 with follow-up data and 270 with the primary outcome measure) from 9 US Neonatal Seizure Registry centers, born from July 2015 to March 2018. The centers all had level IV neonatal intensive care units and comprehensive pediatric epilepsy programs. Data were analyzed from June 2020 to February 2021. Exposures The primary exposure was duration of ASM treatment dichotomized as ASM discontinued vs ASM maintained at the time of discharge from the neonatal seizure admission. To enhance causal association, each outcome risk was adjusted for propensity to receive ASM at discharge. Propensity for ASM maintenance was defined by a logistic regression model including seizure cause, gestational age, therapeutic hypothermia, worst electroencephalogram background, days of electroencephalogram seizures, and discharge examination (allP ≤ .10 in a joint model except cause, which was included for face validity). Main Outcomes and Measures Functional neurodevelopment was assessed by the Warner Initial Developmental Evaluation of Adaptive and Functional Skills (WIDEA-FS) at 24 months powered for propensity-adjusted noninferiority of early ASM discontinuation. Postneonatal epilepsy, a prespecified secondary outcome, was defined per International League Against Epilepsy criteria, determined by parent interview, and corroborated by medical records. Results Most neonates (194 of 303 [64%]) had ASM maintained at the time of hospital discharge. Among 270 children evaluated at 24 months (mean [SD], 23.8 [0.7] months; 147 [54%] were male), the WIDEA-FS score was similar for the infants whose ASMs were discontinued (101 of 270 [37%]) compared with the infants with ASMs maintained (169 of 270 [63%]) at discharge (median score, 165 [interquartile range, 150-175] vs 161 [interquartile range, 129-174];P = .09). The propensity-adjusted average difference was 4 points (90% CI, −3 to 11 points), which met the a priori noninferiority limit of −12 points. The epilepsy risk was similar (11% vs 14%;P = .49), with a propensity-adjusted odds ratio of 1.5 (95% CI, 0.7-3.4;P = .32). Conclusions and Relevance In this comparative effectiveness study, no difference was found in functional neurodevelopment or epilepsy at age 24 months among children whose ASM was discontinued vs maintained at hospital discharge after resolution of acute symptomatic neonatal seizures. These results support discontinuation of ASM prior to hospital discharge for most infants with acute symptomatic neonatal seizures.
📖 Papers frequently viewed together
6 Citations
1 Citations
References42
Newest
#1Vi T. Le (The Research Institute at Nationwide Children's Hospital)H-Index: 3
#2Hibo H. Abdi (The Research Institute at Nationwide Children's Hospital)H-Index: 2
Last. Jonathan L. SlaughterH-Index: 16
view all 8 authors...
Objective This article aims to describe the frequency and characteristics of anticonvulsant medication treatments initiated in the neonatal period. Study Design We analyzed a cohort of neonates with a seizure diagnosis who were discharged from institutions in the Pediatric Health Information System between 2007 and 2016. Adjusted risk ratios and 95% confidence intervals for characteristics associated with neonatal (≤ 28 days postnatal) anticonvulsant initiation were calculated via modified Poiss...
1 CitationsSource
#1Colleen Peyton (NU: Northwestern University)H-Index: 9
#2Michael E. Msall (U of C: University of Chicago)H-Index: 55
Last. Hannah C. GlassH-Index: 37
view all 6 authors...
AIM To determine the concurrent validity of the Warner Initial Developmental Evaluation of Adaptive and Functional Skills (WIDEA-FS), a criterion-specified questionnaire that assesses a child's adaptive skills in everyday contexts, and the Bayley Infant and Toddler Scales of Development, Third Edition (Bayley-III). METHOD In a prospective cohort study, 431 WIDEA-FS and Bayley-III assessments were completed among 341 children, aged 10 to 36 months corrected age (158 females, 183 males; median [in...
Source
#1Colleen Peyton (NU: Northwestern University)H-Index: 9
#3Kristen Wroblewski (U of C: University of Chicago)H-Index: 36
Last. Michael E. Msall (U of C: University of Chicago)H-Index: 55
view all 11 authors...
BACKGROUND The Warner Initial Developmental Evaluation of Adaptive and Functional Skills (WIDEA-FS) is a 50-item, criterion-specified questionnaire that assesses a child's adaptive skills in everyday context and can be used in high-risk follow-up settings to identify risk for adverse neurodevelopmental outcome. Our aim was to validate the WIDEA-FS by comparing a sample of typically developing children to children with special health needs and to compare results to the Capute Scales, which includ...
Source
#1Monica E. Lemmon (Duke University)H-Index: 14
#2Hannah C. Glass (UCSF: University of California, San Francisco)H-Index: 37
Last. Linda S. Franck (UCSF: University of California, San Francisco)H-Index: 67
view all 17 authors...
Objective Neonates with seizures have a high risk of mortality and neurological morbidity. We aimed to describe the experience of parents caring for neonates with seizures. Design This prospective, observational and multicentre (Neonatal Seizure Registry) study enrolled parents of neonates with acute symptomatic seizures. At the time of hospital discharge, parents answered six open-ended response questions that targeted their experience. Responses were analysed using a conventional content analy...
Source
#1Linda S. Franck (UCSF: University of California, San Francisco)H-Index: 67
#2Renée A. Shellhaas (UM: University of Michigan)H-Index: 32
Last. Sonia L. BonifacioH-Index: 24
view all 23 authors...
OBJECTIVE: To characterize and determine risk factors for key dimensions of well-being at hospital discharge in families of neonates with acute symptomatic seizures. STUDY DESIGN: This prospective, observational cohort study enrolled 144 parent-infant dyads among neonates with acute symptomatic seizures from 9 pediatric hospitals in the Neonatal Seizure Registry. One parent per family completed a discharge survey, which included measures of anxiety and depression, health-related quality of life,...
Source
#1Cynthia Sharpe (UCSD: University of California, San Diego)H-Index: 9
#2Gail E. Reiner (UCSD: University of California, San Diego)H-Index: 7
Last. Richard H. Haas (UCSD: University of California, San Diego)H-Index: 44
view all 25 authors...
BACKGROUND AND OBJECTIVES: There are no US Food and Drug Administration–approved therapies for neonatal seizures. Phenobarbital and phenytoin frequently fail to control seizures. There are concerns about the safety of seizure medications in the developing brain. Levetiracetam has proven efficacy and an excellent safety profile in older patients; therefore, there is great interest in its use in neonates. However, randomized studies have not been performed. Our objectives were to study the efficac...
19 CitationsSource
#1Janet S. Soul (Boston Children's Hospital)H-Index: 37
#2Ronit M. PresslerH-Index: 26
Last. Jonathan M. Davis (Floating Hospital for Children)H-Index: 55
view all 18 authors...
Although seizures have a higher incidence in neonates than any other age group and are associated with significant mortality and neurodevelopmental disability, treatment is largely guided by physician preference and tradition, due to a lack of data from welldesigned clinical trials. There is increasing interest in conducting trials of novel drugs to treat neonatal seizures, but the unique characteristics of this disorder and patient population require special consideration with regard to trial d...
16 CitationsSource
#1Maria L.V. Dizon (NU: Northwestern University)H-Index: 11
#2Rakesh Rao (WashU: Washington University in St. Louis)H-Index: 16
Last. An N. MassaroH-Index: 25
view all 13 authors...
Background While intercenter variation (ICV) in anti-epileptic drug (AED) use in neonates with seizures has been previously reported, variation in AED practices across regional NICUs has not been specifically and systematically evaluated. This is important as these centers typically have multidisciplinary neonatal neurocritical care teams and protocolized approaches to treating conditions such as hypoxic ischemic encephalopathy (HIE), a population at high risk for neonatal seizures. To identify ...
3 CitationsSource
#1Hannah C. Glass (UCSF: University of California, San Francisco)H-Index: 37
#2Adam L. Numis (UCSF: University of California, San Francisco)H-Index: 13
Last. Elizabeth E. Rogers (UCSF: University of California, San Francisco)H-Index: 25
view all 5 authors...
Abstract Background Neonatal seizures due to acute brain injury are associated with high rates of death, disability and epilepsy. Our objective was to examine incidence of and risk factors for epilepsy among survivors of acute symptomatic neonatal seizures who were cared for by a Neonatal Neurocritical Care Service. Methods Neonates with acute symptomatic seizures who were admitted to UCSF Benioff Children's Hospital Neuro-Intensive Care Nursery from 7/2008-6/2014 were considered for inclusion. ...
11 CitationsSource
#1Hannah C. Glass (UCSF: University of California, San Francisco)H-Index: 37
#2Zachary M. Grinspan (Cornell University)H-Index: 16
Last. Renée A. Shellhaas (UM: University of Michigan)H-Index: 32
view all 3 authors...
Abstract Acute symptomatic seizures are a common sign of neurological dysfunction and brain injury in neonates and occur in approximately one to three per 1000 live births. Seizures in neonates are usually a sign of underlying brain injury and, as such, are commonly associated with adverse outcomes. Neurological morbidities in survivors often co-occur; epilepsy, cerebral palsy, and intellectual disability often occur together in the most severely affected children. Risk factors for adverse outco...
19 CitationsSource
Cited By1
Newest
#1Eric T. Payne (Alberta Children's Hospital)H-Index: 16
#2Elaine C. Wirrell (Mayo Clinic)H-Index: 63
Source